Patient demographics and baseline disease characteristics (N = 25)
Characteristic . | No. of patients . | % of patients . |
---|---|---|
Age, y | ||
Median | 14 | — |
Range | 1-21 | — |
Sex | ||
Male | 16 | 64 |
Female | 9 | 36 |
Race | ||
Black | 2 | 8 |
American Indian or Alaska Native | 1 | 4 |
Asian | 2 | 8 |
White | 12 | 48 |
Other | 8 | 32 |
Immunophenotype | ||
B-precursor | 21 | 84 |
T cell | 1 | 4 |
Unknown | 3 | 12 |
Prior regimens | ||
Median | 2 | — |
Range | 1-3 | — |
1 regimen* | 4 | 16 |
2 regimens | 14 | 56 |
3 regimens | 7 | 28 |
Refractory to immediate prior regimen | 15 | 60 |
Performance status (Karnofsky/Lansky) | ||
50% | 2 | 8 |
60% | 2 | 8 |
70% | 2 | 8 |
80% | 3 | 12 |
90% | 6 | 24 |
100% | 10 | 40 |
Prior HSCT† | 4 | 16 |
Characteristic . | No. of patients . | % of patients . |
---|---|---|
Age, y | ||
Median | 14 | — |
Range | 1-21 | — |
Sex | ||
Male | 16 | 64 |
Female | 9 | 36 |
Race | ||
Black | 2 | 8 |
American Indian or Alaska Native | 1 | 4 |
Asian | 2 | 8 |
White | 12 | 48 |
Other | 8 | 32 |
Immunophenotype | ||
B-precursor | 21 | 84 |
T cell | 1 | 4 |
Unknown | 3 | 12 |
Prior regimens | ||
Median | 2 | — |
Range | 1-3 | — |
1 regimen* | 4 | 16 |
2 regimens | 14 | 56 |
3 regimens | 7 | 28 |
Refractory to immediate prior regimen | 15 | 60 |
Performance status (Karnofsky/Lansky) | ||
50% | 2 | 8 |
60% | 2 | 8 |
70% | 2 | 8 |
80% | 3 | 12 |
90% | 6 | 24 |
100% | 10 | 40 |
Prior HSCT† | 4 | 16 |